Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more
Shanghai Hile Bio-tech (603718) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.001x
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) has a cash flow conversion efficiency ratio of -0.001x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-1.18 Million) by net assets (CN¥1.70 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Hile Bio-tech - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Shanghai Hile Bio-tech's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shanghai Hile Bio-tech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Hile Bio-tech ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xinjiang Tianshun Supply Chain Co Ltd
SHE:002800
|
-0.079x |
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
0.024x |
|
Lydia Yesil Enerji Kaynaklari A.S.
IS:LYDYE
|
N/A |
|
Guilin Tourism Corp Ltd
SHE:000978
|
0.059x |
|
Duni AB (publ)
PINK:DUNNF
|
0.044x |
|
Talon Capital Corp. Class A Ordinary Shares
NASDAQ:TLNC
|
N/A |
|
Jacquet Metal Service SA
PA:JCQ
|
0.059x |
|
Hudson Technologies Inc
NASDAQ:HDSN
|
0.033x |
Annual Cash Flow Conversion Efficiency for Shanghai Hile Bio-tech (2011–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Hile Bio-tech from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.70 Billion | CN¥46.47 Million | 0.027x | +1190.98% |
| 2023-12-31 | CN¥1.17 Billion | CN¥-2.94 Million | -0.003x | -100.95% |
| 2022-12-31 | CN¥1.11 Billion | CN¥292.91 Million | 0.264x | +496.48% |
| 2021-12-31 | CN¥987.19 Million | CN¥43.63 Million | 0.044x | -74.64% |
| 2020-12-31 | CN¥962.20 Million | CN¥167.68 Million | 0.174x | +191.93% |
| 2019-12-31 | CN¥992.57 Million | CN¥59.25 Million | 0.060x | +223.68% |
| 2018-12-31 | CN¥1.03 Billion | CN¥18.92 Million | 0.018x | -43.23% |
| 2017-12-31 | CN¥1.07 Billion | CN¥34.92 Million | 0.032x | -69.87% |
| 2016-12-31 | CN¥1.01 Billion | CN¥108.39 Million | 0.108x | -48.51% |
| 2015-12-31 | CN¥963.31 Million | CN¥201.69 Million | 0.209x | +6.09% |
| 2014-12-31 | CN¥558.50 Million | CN¥110.22 Million | 0.197x | -33.07% |
| 2013-12-31 | CN¥500.66 Million | CN¥147.63 Million | 0.295x | +12.64% |
| 2012-12-31 | CN¥467.89 Million | CN¥122.48 Million | 0.262x | -29.01% |
| 2011-12-31 | CN¥405.74 Million | CN¥149.61 Million | 0.369x | -- |